01—Abstract
Summary
Summary of the 8-K/A filed May 13, 2022. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. (MRNA) filed an amendment to its Form 8-K on May 13, 2022, to provide further details regarding the departure of its Chief Financial Officer, Jorge Gomez, which originally occurred on May 10, 2022.
While Mr. Gomez was initially set to receive standard severance benefits, including 12 months of salary and COBRA coverage, the amended filing clarifies the terms of an Executive Separation Agreement and Release. This agreement introduces a clawback provision that allows Moderna to terminate or seek repayment of severance benefits if Mr. Gomez is found to have engaged in wrongdoing or faces penalties related to an internal investigation by Dentsply Sirona or the SEC.
This addition is significant for investors as it introduces a contingency to the executive's separation package tied to potential past conduct. The company also entered into this agreement in consideration for a general release of claims from Mr. Gomez.
02—Key points
Key Highlights
- Amendment to original Form 8-K filed on May 13, 2022, regarding CFO Jorge Gomez's departure.
- CFO Jorge Gomez departed on May 10, 2022.
- Mr. Gomez was initially eligible for 12 months' salary ($700,000) and 12 months of COBRA coverage as severance.
- An Executive Separation Agreement and Release was entered into on May 13, 2022.
- Moderna has the right to terminate or seek repayment of severance benefits under specific conditions.
- These conditions include Mr. Gomez engaging in wrongdoing or facing penalties/disgorgement from investigations by Dentsply Sirona or the SEC related to Dentsply's disclosures.
- In exchange for severance, Mr. Gomez provided a general release of claims against Moderna.
03—Questions
Frequently Asked Questions
What is the main reason for this 8-K/A filing?
This 8-K/A filing is an amendment to a previous 8-K. It provides additional details and clarifies the terms of the separation agreement between Moderna and its former CFO, Jorge Gomez, particularly concerning potential clawbacks of his severance benefits.
What are the specific conditions under which Moderna can reclaim Mr. Gomez's severance pay?
Moderna can terminate or seek repayment of Mr. Gomez's severance benefits if the company determines, at its sole discretion, that Mr. Gomez engaged in any wrongdoing or is required to pay a fine, penalty, or disgorgement in any investigation by Dentsply Sirona or the SEC related to Dentsply's public disclosures and ongoing internal investigation.
What does the Executive Separation Agreement require from Mr. Gomez?
In consideration for the severance benefits, Mr. Gomez agreed to a general release of all claims against Moderna. This means he is waiving his right to sue the company for any issues arising during his employment.
Are there any ongoing investigations mentioned that could impact Mr. Gomez's severance?
Yes, the filing mentions potential investigations by Dentsply Sirona or the SEC related to public disclosures made by Dentsply regarding an internal investigation into certain matters. Mr. Gomez's severance is contingent on not facing penalties or engaging in wrongdoing in connection with these potential investigations.
04—Continue